Shilajit

Shilajit

Shilajit is sold as a Himalayan resin, a fulvic-acid concentrate, a testosterone booster, and a mitochondrial tonic. Those are four objects. The chemistry is a geographically variable exudate. The human file is small and often sponsor-adjacent. The product-quality file is the load-bearing clinical question. This article keeps those layers apart. It is a research review. It is not medical advice.

Compiled by South Beach Longevity · 20 August 2026 Copyright 2026 Series SBL-41 / SP-SHILAJIT · Register A scientific article Sources peer-reviewed chemistry, labelled reviews, human trials, elemental analyses, and agency-adjacent metal literature · verified NCBI records Constraint This document describes published research. It is not medical advice. No human use, dose, route or schedule is recommended anywhere in this document.

How to read this document Every finding is labelled, in the sentence that reports it, by the kind of study that produced it. A rock exudate is not a molecule. A rasayana classification is not an outcome trial. A rise in serum testosterone in healthy middle-aged men is not testosterone-replacement therapy. A fulvic-acid percentage is not a clinical endpoint. A rat fatigue model is not a human energy claim. Amounts appear only as reported experimental or registry parameters, always with the population attached. Nothing here is a recommendation. Findings are graded in place as established, strongly supported, emerging, plausible, or speculative. Two further labels mark careful absences rather than verdicts: not established, where the evidence is too thin to place a claim on the ladder at all — untested or insufficient, an absence of proof rather than disproof; and not supported, where the weight of evidence leans against a claim but stops short of a formal refutation.

01 Names, and why they do not settle the chemistry

The English trade name is shilajit. The same exudate travels as mumie, mumijo, moomiyo, mummiyo, asphaltum punjabianum, mineral pitch, and, in Tibetan registers, zhaxun (Stohs, 2014; Ding et al., 2020). A name is a pointer. It is not a structure.

Ghosal, Reddy, and Lal published the first MEDLINE-indexed chemical paper under the title Shilajit I: chemical constituents (Ghosal, Reddy, and Lal, 1976). That paper is established as the modern chemical opening. The MEDLINE record carries no abstract. This article will not invent a constituent list from that title.

What later reviews can be held to is more modest. Agarwal, Khanna, Karmarkar, Anwer, and Khar described shilajit as a pale-brown to blackish-brown exudation of variable consistency from rock layers, especially the Himalaya and Hindu Kush, consisting of a complex mixture of organic humic substances and plant and microbial metabolites from the rock rhizosphere (Agarwal et al., 2007). That is a review. It is strongly supported as a working description of the object. It is not a specification sheet.

Wilson and colleagues, writing from Ayurvedic and Siddha sources plus a biomedical database sweep, called shilajit a multi-component naturally occurring mineral substance and recorded the rasayana / rasayanam classification — rejuvenator, preventer of ailment, enhancer of quality of life (Wilson et al., 2011). They then refused the next step. After scanning classical texts, selected theses, and published papers, they judged that shilajit “unfortunately lacks scientific evaluation and systematic documentation,” that in-vivo antioxidant work had used an irrelevant dose without a positive control, that immunomodulatory activity “currently may be considered as unproven,” and that “the bioactivity of shilajit lacks substantial evidence” (Wilson et al., 2011). That 2011 refusal is load-bearing. Later marketing that treats rasayana status as settled pharmacology is quoting a classification Wilson already separated from proof.

02 Geological and biological origin

The origin story is not one plant. Ding, Zhao, Fan, Hu, Wang, Zhong, and Gu investigated Tibetan exudation points at 2,000–4,000 m and described a water-soluble black paste mixed with feces of Trodocterus or Ochotona (pika) species, flowing from pores and structural planes in slate, carbonaceous slate, and sandy slate of Triassic strata and early Mesozoic granitoids (Ding et al., 2020). Organic matter was stored in intergranular pores, dissolved pores, joints, and fractures and exuded when the storage environment changed. The points sat on sunny steep slopes and cliffs of 60° or more, in cavities rain did not wash (Ding et al., 2020). That paper is field geology. It is strongly supported as evidence that the object is a rock-hosted organic exudate with an animal contribution at the point of appearance. It is not a manufacturing article.

Agarwal’s review already placed plant and microbial metabolites in the rhizosphere (Agarwal et al., 2007). The two accounts agree on mixture and refuse a single botanical identity. A capsule labelled “Himalayan plant resin” is a commercial sentence. It is not Ding’s cliff.

Antarctic “mumijo” must be kept off this line. Aiello, Fattorusso, Menna, Vitalone, Schröder, and Müller analysed a yellow fossil material from snow petrels (Pagodroma nivea) and found a mixture of glycerol derivatives, not the Himalayan humic complex (Aiello et al., 2011). In cortical neurons the extract was neuroprotective against amyloid-β 25–35; a glycerol-ether/wax-ester fraction promoted growth in PC12 cells (Aiello et al., 2011). That is a different object. Sharing a folk name does not share a chemistry.

03 Geographic variability

If the object is a cliff exudate, geography is not flavour. It is composition. Agarwal’s review already named Himalayan and Hindu Kush ranges and “many mountain ranges of the world” (Agarwal et al., 2007). Ding’s Tibetan points were lithologically specific (Ding et al., 2020). Schepetkin and colleagues fractionated crude mumie — they do not claim a single Himalayan cliff — into fulvic acid, humic acid, humin, hymatomelanic acid, and two low-molecular-weight fractions, then five fulvic subfractions (Schepetkin et al., 2003). Solubility tracked polar versus nonpolar content. Biological assays were run only on fulvic fractions, in murine macrophages and splenocytes (Schepetkin et al., 2003). That is analytical chemistry plus mouse immunology. It is strongly supported as evidence that “mumie” is a family of fractions, not a reagent-grade solid.

Aldakheel, Gondal, Alsayed, Almessiere, Nasr, and Shemsi compared two widely sold kinds, labelled Indian and Pakistani, by laser-induced breakdown spectroscopy, ICP-OES/MS, and EDX (Aldakheel et al., 2022). Both were enriched in calcium, sulphur, and potassium and contained aluminium, strontium, manganese, barium, zinc, nickel, boron, chromium, lead, arsenic, and mercury in amounts the authors judged above standard permissible limits; mercury and titanium were detected only in the Indian samples (Aldakheel et al., 2022). That paper is elemental analysis of sold material. Geographic labels on a pouch were already enough to change the toxin list. They are not enough to guarantee a clean lot.

A later Tibetan methods paper treated sample scarcity itself as a quality problem: plateau material is hard to collect in numbers that support pattern recognition, so HPLC and FTIR libraries are thin (Ding et al., 2024). Scarcity is not mystique. It is a sampling bias.

04 Fulvic substances

Fulvic acids are the water-soluble, lower-molecular-weight slice of humic matter. They are a class, not a drug. Schepetkin’s FA1 and FA2 fractions increased reactive oxygen species and nitric oxide in murine peritoneal macrophages; FA1 increased thymidine uptake in splenocytes; the ROS and nitric-oxide signals tracked carbohydrate content (Schepetkin et al., 2003). That is mouse macrophage redox. It is emerging as immunomodulatory chemistry in that system. It is not a human vitality endpoint.

Schepetkin, Xie, Jutila, and Quinn later reported complement-fixing activity of fulvic acid from shilajit and other natural sources (Schepetkin et al., 2009). Again, a biochemical activity. The authors noted that fulvic acid is often nominated as the therapeutic principle and that little was known about its physical chemistry (Schepetkin et al., 2009). Nomination is not proof.

Surapaneni and colleagues standardised a processed shilajit used in a rat chronic-fatigue model to dibenzo-α-pyrones 0.43% w/w, dibenzo-α-pyrone chromoproteins 20.45% w/w, and fulvic acids 56.75% w/w (Surapaneni et al., 2012). That assay is the most precise fulvic number in this review. It describes one processed lot in one animal model. It does not travel to a retail jar that prints “60% fulvic acid” without the same method, the same lot, and the same outcome.

Agarwal’s group also used fulvic acid extracted from shilajit as a complexing agent for furosemide, to change solubility, dissolution, and permeability (Agarwal, Anwer, and Aqil, 2008). That is pharmaceutical materials science. It treats fulvic acid as an excipient. It is not an efficacy trial of shilajit.

Do not assume that a high fulvic-acid percentage establishes efficacy. The sentence is the thesis of this section and of the article. An assay is a description of a fraction. Efficacy is a human endpoint on a named preparation. The two meet only when a trial measures both and pre-specifies the link. No trial in this review does that job at a level that would retire the warning.

05 Humic substances

Humic acids are the higher-molecular-weight, alkali-soluble, acid-insoluble neighbours of fulvic acids. Schepetkin isolated them from mumie as a distinct fraction (Schepetkin et al., 2003). Mirza and colleagues extracted humic acid from shilajit and tested it as an oral-delivery carrier for carbamazepine (Mirza et al., 2011). Comparative work from the same laboratory evaluated humic substances in oral drug delivery more broadly (Mirza et al., 2011, Results Pharma Sci). Those papers are delivery chemistry. They do not make humic acid a longevity nutrient.

Zhernov and colleagues compared antiviral activity of characterised humic substances from coal, peat, and peloids with water-soluble organic matter from shilajit samples against HIV-1, relating activity to structure (Zhernov et al., 2021). That is in-vitro virology. It is plausible as a structure–activity observation. It is not a clinical antiretroviral claim, and this article will not promote one.

Socol’s clinical review of humic acid as an antiviral is a review of a soil-humeome literature (Socol, 2022). Reviews map hypotheses. They do not create human outcomes.

06 Dibenzo-α-pyrones where they apply

Dibenzo-α-pyrones (DBPs) and DBP-chromoproteins appear in processed-shilajit standardisation, not as a free-standing human drug class. Surapaneni’s rat CFS preparation carried 0.43% w/w DBPs and 20.45% w/w chromoproteins (Surapaneni et al., 2012). Keller, Housh, Hill, Smith, Schmidt, and Johnson described PrimaVie shilajit as a “fluvic mineral complex” — their spelling — composed of fulvic acids, dibenzo-α-pyrones, proteins, and minerals (Keller et al., 2019). Stohs, in a safety-and-efficacy review, nominated DBPs and fulvic acid and their derivatives as key constituents for the effects he catalogued (Stohs, 2014).

Nomination from a review is not a reconstitution. This review does not contain a human trial that isolates a single DBP as the active pharmaceutical ingredient. Urolithin language sometimes drifts toward this family in trade copy. This article will not launder a gut-microbiome urolithin literature into shilajit without a primary paper that makes that identification on the exudate. None in the verified store does.

07 Purification and standardization

“Processed shilajit” and “purified shilajit” are the phrases the human papers use. Biswas and colleagues administered processed shilajit capsules in oligospermia (Biswas et al., 2010). Pandit and colleagues administered purified shilajit in healthy men (Pandit et al., 2016). Das and colleagues used Natreon Inc.’s PrimaVie, described as a patented extract standardised to not less than 60.3% fulvic-acid equivalents with dibenzo-α-pyrones and chromoproteins, manufactured, the authors wrote, to reduce lead and arsenic to less than 1 ppm and mercury to less than 0.1 ppm (Das et al., 2016). Natreon supplied the capsules and partial funding (Das et al., 2016). Keller used the same brand at two daily amounts versus placebo, quoting a specification of ≥50.0% fulvic acid plus 10% free and conjugated DBPs (Keller et al., 2019). Das’s later skin study again used PrimaVie supplied by Natreon, with a Natreon research grant (Das et al., 2019). Pingali and Nutalapati used a standardised aqueous extract in osteopenia (Pingali and Nutalapati, 2022). A manufacturer’s metal-reduction sentence is a process claim. It is not Aldakheel’s assay of unnamed sold pouches, and it is not a third-party certificate attached to every retail lot that borrows the word shilajit.

Those names are not interchangeable. A processed capsule in Kolkata in 2010 is not PrimaVie in a Nebraska strength lab in 2019. Standardisation, where it is reported at all, is to fulvic acid, DBPs, or a brand method. There is no pharmacopoeial article in this review that makes “shilajit” one assayable drug substance.

Purification is also the safety claim the market leans on. The claim is testable. It is tested in Part Four. Until a lot is assayed, “purified” is an adjective.

08 Rasayana language

Ayurvedic and Siddha sources classify shilajit as rasayana (Wilson et al., 2011). Wilson counted use in twenty Sastric formulations and twenty-four proprietary drugs for “extraneous indications” (Wilson et al., 2011). Meena, Pandey, Arya, and Ahmed, in an Ayurveda-research journal, offered shilajit as a “panacea for high-altitude problems” — hypoxia, acute mountain sickness, oedema, insomnia, tiredness, anorexia, pain, dementia, depression — without a randomised human trial in that paper (Meena et al., 2010). The paper is ethnographic and speculative physiology. It is not an altitude RCT.

Bucci’s exercise-herb review listed many traditional performance herbs and noted that scientific scrutiny with controlled trials was recent (Bucci, 2000). Shilajit sits in that older list. A list is not a result.

This article records traditional use as history. History can motivate a trial. It cannot substitute for one. Treating rasayana status as efficacy evidence is the first red-team challenge, and it is refused.

09 What Wilson 2011 already refused

Wilson’s review is the cleanest internal critique in the traditional literature this review contains. The authors did not deny use. They denied that use had been converted into evidence: antioxidant assays at irrelevant doses, immunomodulation that failed critical assessment, bioactivity without substantial support (Wilson et al., 2011). A later review that restores “miraculous healing properties” language (Agarwal et al., 2007, closing sentence) is a reviewer’s cadence. It is not a new experiment.

Stohs (2014) is the opposite pressure. He wrote that safety is “well documented,” that animal and human studies support spermatogenesis, and that animal and human data support use as a “revitalizer,” enhancing physical performance and relieving fatigue “with enhanced production of ATP” (Stohs, 2014). That ATP clause is the mitochondrial-energy claim in review clothing. The human papers Stohs could have had in 2014 were essentially Biswas 2010 and not Keller 2019 or Pandit 2016. A review that outruns its human file is not a substitute for the file.

10 The mitochondrial-energy sentence

Surapaneni’s group reported that processed shilajit attenuated behavioural symptoms in a rat model of chronic fatigue syndrome, with the authors attributing the effect to modulation of the hypothalamic–pituitary–adrenal axis and mitochondrial bioenergetics (Surapaneni et al., 2012). The objects are rats, a forced-fatigue paradigm, and isolated-mitochondria readouts. The paper is emerging as preclinical pharmacology. It is not a human chronic-fatigue trial. It is not an ATP capsule.

No paper in the verified store measures human skeletal-muscle ATP, PCr recovery, or VO₂ kinetics as a primary endpoint after shilajit. Keller’s discussion leans on a mouse forced-swim study (Bhattacharyya and colleagues, as cited there) in which PrimaVie raised post-exercise muscle ATP, and on an unpublished six-person Harvard Step Test pilot (Keller et al., 2019). That is the actual chain: mouse ATP, then inference. Keller measured strength retention and serum hydroxyproline after a fatiguing protocol (Keller et al., 2019). That is closer to connective-tissue and force than to mitochondria. Das measured ECM gene expression in muscle biopsies (Das et al., 2016). Transcripts are not joules.

Vague “mitochondrial energy” marketing is the sixth red-team challenge. It is refused except where a paper names the species, the organelle assay, and the limitation.

11 How to read the human file

The human file that can be named without leaving the verified store is short. The table in the Apparatus is the census. The rule is simple. Each outcome keeps the preparation, the design, the n that the paper actually states, and the endpoint that was measured. Sponsor adjacency is named when authors or brands make it visible. Small sponsor-funded trials are the third red-team challenge: they are not deleted; they are not promoted into consensus.

Morgado and colleagues, in a 2024 systematic review of “testosterone boosters,” judged purified shilajit extract (PrimaVie) “possibly effective” for men with late-onset hypogonadism (Morgado et al., 2024). Pandit’s trial enrolled healthy volunteers aged 45–55 years, not a diagnosed hypogonadal clinic population (Pandit et al., 2016). A systematic review that relocates that trial into late-onset hypogonadism is doing interpretive work. This article keeps Pandit’s population.

12 Testosterone

Pandit, Biswas, Jana, De, Mukhopadhyay, and Biswas reported a randomised, double-blind, placebo-controlled study of purified shilajit, 250 mg twice daily for 90 consecutive days, in healthy male volunteers aged 45–55 years (Pandit et al., 2016). Versus placebo, total testosterone, free testosterone, and DHEAS increased (p < 0.05). LH and FSH were “well maintained” (Pandit et al., 2016). The MEDLINE abstract does not report sample size or the magnitude of the hormone change. This article will not invent either number.

That paper is a human hormone RCT. It is emerging as evidence that this purified preparation can move circulating androgens in healthy middle-aged men over three months. It is not a trial in androgen-deficient men. It is not a fertility trial. It is not a body-composition trial. It is not TRT. Testosterone marketing that treats Pandit as replacement therapy is the second red-team challenge, and it is refused.

Biswas and colleagues, in an uncontrolled series, reported a 23.5% rise in serum testosterone (p < 0.001) after processed shilajit 100 mg twice daily for 90 days in men who completed an oligospermia protocol (Biswas et al., 2010). That rise is a within-subject change without a placebo arm. It cannot carry a testosterone-booster claim.

Park, Kim, and Han reported higher epididymal and testicular sperm counts in rats after six weeks of oral shilajit (Park et al., 2006). That is rat histology. It is not a human androgen study.

13 Male fertility

Biswas and colleagues screened 60 infertile men and enrolled 35 with total sperm counts below 20 million ml⁻¹ (Biswas et al., 2010). Processed shilajit 100 mg twice daily after major meals for 90 days. Twenty-eight completers: spermia +37.6%, total sperm count +61.4%, motility improved 12.4–17.4% at stated intervals, morphologically normal count +18.9%, semen malondialdehyde −18.7%, testosterone +23.5% (p < 0.001), FSH +9.4% (p < 0.05), versus baseline (Biswas et al., 2010). HPLC detected processed-shilajit constituents in semen. Hepatic and renal profiles were unaltered at the given amount (Biswas et al., 2010). Publication type is Clinical Trial, not Randomized Controlled Trial. There is no placebo group in the abstract.

That series is emerging as an open-label spermatogenic signal on processed shilajit. It is not a live-birth trial. It is not independent confirmation of Pandit. Several authors overlap the later testosterone RCT. Overlap is not misconduct; it is not independence.

Mishra, Jain, and Singh reported profertility effects of shilajit against cadmium-induced infertility in male mice (Mishra et al., 2018). Animal rescue of a toxin model is not human oligospermia.

A 2024 Cureus case mixed organophosphate exposure with “traditional medicinal interventions” in a couple trying to conceive (Mathiya et al., 2024). A case is a case. It is not a fertility programme.

14 Fatigue and exercise

Keller and colleagues assigned recreationally trained men to PrimaVie 250 mg·d⁻¹, 500 mg·d⁻¹, or placebo for eight weeks (n = 21 per group) and tested maximal voluntary isometric contraction, concentric peak torque, and serum hydroxyproline around a fatiguing protocol (Keller et al., 2019). The statistically significant contrasts after supplementation sat in the upper 50th percentile of pre-supplementation MVIC: adjusted mean percent decline in MVIC was 8.9 ± 2.3% (high dose) versus 17.0 ± 2.4% (low dose, p = 0.022) and 16.0 ± 2.4% (placebo, p = 0.044). Baseline hydroxyproline was lower after the high dose than after low dose or placebo in that same high-baseline slice (Keller et al., 2019). The authors concluded that 500 mg·d⁻¹ promoted retention of maximal strength after fatigue and decreased baseline hydroxyproline (Keller et al., 2019).

That paper is a human performance RCT on a named brand. It is emerging for a subgroup-defined strength-retention signal. It is not a whole-sample victory. Dichotomising at the median after the fact is a methodological pressure, not a footnote. It is not a mitochondrial assay. It is not an aging trial.

Das and colleagues (NCT02026414) gave PrimaVie 250 mg twice daily for eight weeks, then four more weeks with treadmill exercise, to adult overweight/class I obese US subjects (Das et al., 2016). Natreon supplied the product and partial funding; an author affiliation was Natreon India (Das et al., 2016). Blood glucose, lipids, creatine kinase, and myoglobin did not change. Microarray found 17 ECM-related probe sets upregulated in muscle versus baseline, including tenascin XB, decorin, myoferlin, collagen, elastin, fibrillin 1, and fibronectin 1, confirmed by RT-PCR (Das et al., 2016). The paper is a human muscle-transcriptome study. It is emerging as a gene-expression signal. It is not a strength, VO₂, or fatigue-outcome trial. “Maiden evidence” of mechanotransduction language is the authors’ inference.

Neltner and colleagues randomised 35 recreationally trained men to 500 mg·d⁻¹, 1,000 mg·d⁻¹, or placebo for eight weeks and measured serum pro-c1α1 (Neltner et al., 2024). Both shilajit groups increased pro-c1α1; placebo did not. A greater proportion of the high-dose group than placebo exceeded a minimal clinically important difference (75% versus 30%, p = 0.03) (Neltner et al., 2024). That is a circulating collagen-synthesis biomarker RCT. It is not a tendon-injury trial and not a performance trial.

Bucci’s 2000 review remains the right caution for the whole exercise-herb shelf (Bucci, 2000).

15 Cognition

Carrasco-Gallardo, Guzmán, and Maccioni reviewed shilajit as a “natural phytocomplex with potential procognitive activity,” pointing at fulvic acid and a possible interaction with tau (Carrasco-Gallardo et al., 2012). The same group discussed a formulation containing shilajit and B vitamins as a potential Alzheimer’s nutraceutical (Carrasco-Gallardo et al., 2012, Arch Med Res). Later reviews from the Maccioni circle restated nutraceutical prevention language (Calfio et al., 2020; Maccioni et al., 2022). Andrade and colleagues described “Andean shilajit” as a novel neuroprotective candidate (Andrade et al., 2023). Those papers are reviews and preclinical framing. This review does not contain a completed human cognition RCT with a named shilajit preparation and a pre-specified cognitive primary endpoint.

Schliebs and colleagues reported that defined extracts of Withania and shilajit differentially affected cholinergic markers in rat brain (Schliebs et al., 1997). Rat neurochemistry is not a memory trial.

Cognition therefore remains speculative as a human clinical claim and plausible only as a hypothesis generator. Potential is not prevention.

16 Bone

Pingali and Nutalapati randomised 60 postmenopausal women aged 45–65 years with osteopenia to placebo, 250 mg, or 500 mg of a standardised aqueous shilajit extract daily for 48 weeks (Pingali and Nutalapati, 2022). Lumbar-spine and femoral-neck BMD fell on placebo and was attenuated, dose-dependently, with extract; percentage changes from baseline at 24 and 48 weeks favoured both extract groups versus placebo (p < 0.001). CTX-1, BALP, and RANKL fell and OPG rose on extract, not placebo. MDA fell and GSH rose from week 12; hsCRP fell progressively (Pingali and Nutalapati, 2022). The authors attributed part of the effect to attenuated turnover, inflammation, and oxidative stress after estrogen withdrawal.

That paper is the strongest human clinical trial in this review on a structural endpoint. It is emerging to strongly supported as a BMD-preservation signal on this extract in this population. It is not a fracture trial. It is not a menopausal-hormone comparison. A single-centre extract study can be true and still be too small to set practice.

Sadeghi and colleagues reviewed oral momiai / shilajit for bone repair in Persian medicine and found the clinical documentation thin (Sadeghi et al., 2020). Kangari and colleagues reported accelerated osteogenic differentiation of human adipose-derived mesenchymal stem cells in 2D and 3D culture (Kangari et al., 2022). Alshubaily and Jambi loaded shilajit into chitosan nanoparticles in an osteoporotic rat model (Alshubaily and Jambi, 2022). Those are cell and animal papers. They do not duplicate Pingali.

17 Metabolic health

Das 2016 reported no change in blood glucose or lipids after eight plus four weeks of oral extract in overweight/class I obese adults (Das et al., 2016). That is a null metabolic panel on a short transcript study. It is not a diabetes trial.

Ghezelbash, Shahrokhi, Khaksari, Ghaderi-Pakdel, and Asadikaram reported hepatoprotective effects of shilajit in rats with high-fat-diet NAFLD (Ghezelbash et al., 2020), and a later paper from the group reported cytokine and adipokine changes in the same model (Ghezelbash et al., 2022). Rat NAFLD is not human metabolic syndrome.

Stohs listed “anti-dyslipidemic” among properties in a review (Stohs, 2014). A review list is not a lipid RCT.

Metabolic health in humans is therefore not established. The best human metabolic statement in the store is Das’s unchanged glucose and lipids.

18 Aging, collagen, and skin transcripts

No paper in this review measures all-cause mortality, validated aging clocks, or disability as a function of shilajit. Aging claims are speculative.

What exists are surrogate aging-adjacent readouts. Das and colleagues (NCT02762032) supplemented healthy adult women with PrimaVie 125 or 250 mg twice daily for 14 weeks; the higher amount improved skin perfusion versus baseline or placebo (dermascopic MATLAB analysis, n = 13 in the published figure), and pathway analysis flagged endothelial-migration, vessel-growth, and ECM genes, confirmed by RT-PCR (Das et al., 2019). Natreon supplied capsules and a research grant (Das et al., 2019). No adverse effect was reported in that window (Das et al., 2019). That is a skin-transcript and microperfusion RCT. It is not a wrinkle, ulcer, or longevity trial.

Neltner’s pro-c1α1 rise is a collagen-synthesis biomarker in young trained men (Neltner et al., 2024). Pingali’s BMD preservation is a bone-density signal in osteopenic women (Pingali and Nutalapati, 2022). Those are the aging-adjacent human objects. They are not a healthspan programme.

19 The quality problem is the clinical problem

If the object varies by cliff, season, animal contribution, and processing, then a human trial on a named extract does not underwrite a resin scraped from a roadside stall. Composition variability is the fourth red-team challenge. Product quality is not a late appendix. It is the condition for believing any later sentence about hormones, sperm, bone, or fatigue.

Ding already said that uncertain origin “severely impedes its safety and efficacy in clinical application” (Ding et al., 2020). Wilson said systematic documentation was missing (Wilson et al., 2011). Aldakheel said elemental analysis was “imperative” because the product is consumed as a rejuvenator (Aldakheel et al., 2022). Those three sentences, from geology, traditional review, and analytical chemistry, are the brief for this Part.

20 Heavy metals as a class

Saper, Phillips, Sehgal, Khouri, Davis, Paquin, Thuppil, and Kales purchased 193 Ayurvedic medicines via the internet in 2005 and found lead, mercury, or arsenic in 20.7% (95% CI 15.2–27.1%) (Saper et al., 2008). US-manufactured products (21.7%) did not differ from Indian-manufactured (19.5%). Rasa shastra products had a higher prevalence (40.6% versus 17.1%) and higher median lead and mercury. Among metal-containing products, 95% were sold on US websites and 75% claimed Good Manufacturing Practices. All metal-containing products exceeded one or more acceptable daily-intake standards (Saper et al., 2008). That paper is established as class evidence that Ayurvedic oral products sold to US buyers can carry toxic metals, and that a GMP sentence on a website is not a clearance.

Hore, Alex-Oni, Sedlar, Patel, and Saper later described 584 New York City remedy samples collected during poisoning investigations and store surveys, 2010–2019 (Hore et al., 2022). Blood lead among adult rasa shastra users associated with estimated cumulative daily lead; mean blood lead was higher than among users of other non-Ayurvedic remedies (Hore et al., 2022). The public-health implication they drew was primary prevention in the country of origin, not a consumer-education sticker.

Bhalla and Pannu, sampling common over-the-counter Indian Ayurvedic preparations, asked whether those medications are a “store house of heavy metals” (Bhalla and Pannu, 2022). Sadler and Bell reported Ayurvedic plumbism in a 64-year-old man with very high lead levels taking Ayurvedic medicines for diabetes (Sadler and Bell, 2017). Gitelman, An, Spilchuk, and Kim reported lead toxicity from Ayurvedic medicines in CMAJ (Gitelman et al., 2023). Those papers are class and case. They are not a shilajit-specific census. They are the background risk any unassayed herbo-mineral product inherits.

Abdalla and Smith measured mercury in Ayurvedic dietary supplements that are not rasa shastra, listing Shilajit among the named products, by ICP-MS and a direct mercury analyser (Abdalla and Smith, 2013). Inclusion on that list is established as evidence that shilajit has been an analytical target for mercury. The abstract does not quote the shilajit-specific concentration. This article will not invent one.

21 Arsenic, lead, and mercury in named shilajit

Aldakheel’s comparative analysis is the paper that names the product (Aldakheel et al., 2022). Indian and Pakistani commercial shilajit contained Pb, As, and Hg (Hg in Indian samples) among a longer toxin list, in amounts the authors said exceeded permissible limits, using three orthogonal techniques whose quantitative results agreed (Aldakheel et al., 2022). That is strongly supported as evidence that sold shilajit, not a hypothetical adulterant, can fail a metal gate. It is one sampling frame. It is not every lot on earth. It is enough to retire the sentence “it is a mineral, therefore it is food-like.”

Hussain and Saeed reviewed roles of heavy metals and humic substances in shilajit, including proposed detoxification mechanisms by humic matter (Hussain and Saeed, 2024). A review that discusses detoxification chemistry must not be inverted into a claim that humic acids make lead safe to swallow. Humic binding in a beaker is not a chelation clinic.

Panta, Bhandari, Lamsal, and Adhikari characterised some heavy-metal-containing Ayurvedic drugs and their antibacterial performance (Panta et al., 2018). Intentional rasa shastra addition of metals is a different manufacturing philosophy from accidental contamination. Both can put arsenic, lead, or mercury into an oral product. Neither is a reason to treat an unlabelled resin as standardised.

22 Microbial and other contamination

The verified store is thinner on microbes than on metals. Aabed and colleagues tested aqueous extracts of myrtle and asphaltum punjabianum (“shilajeet”) against P. aeruginosa, E. coli, S. aureus, and C. albicans (Aabed et al., 2020). That is in-vitro antimicrobial screening, not a survey of product bioburden.

Musthafa and colleagues enriched prawn and tilapia diets with shilajit and reported immune and disease-resistance changes against Aeromonas hydrophila (Musthafa et al., 2016; Musthafa et al., 2018). Those are aquaculture papers. They are not human food-microbiology.

Ding’s description of exudate mixed with pika feces is the origin-level microbial risk (Ding et al., 2020). Raw material that includes animal feces is a purification problem before it is a marketing story. This review does not contain a systematic colony-count survey of retail shilajit. The gap is named, not filled.

23 Unprocessed and raw shilajit

Raw resin is the left rung of Figure 2. It maximises identity uncertainty and the fecal/geological metal path Ding and Aldakheel describe. Folklore that treats raw Himalayan resin as more authentic, therefore safer or stronger, inverts the quality file. Authenticity-as-safety is refused.

Processed and purified preparations are the objects in Biswas, Pandit, Das, Keller, Pingali, and Neltner. Processing is not a guarantee. It is a necessary condition for talking about a trial at all.

24 Purification claims and third-party testing

“Purified,” “processed,” “standardised,” and “third-party tested” are four different sentences.

Purified/processed: used by trialists; method often opaque in MEDLINE abstracts (Biswas et al., 2010; Pandit et al., 2016).

Standardised: Surapaneni published percentages for one rat lot (Surapaneni et al., 2012); Keller named PrimaVie; Pingali named a standardised aqueous extract. A percentage without a method is a marketing integer.

Third-party tested: Saper found that 75% of metal-containing Ayurvedic products claimed GMP (Saper et al., 2008). The claim and the X-ray fluorescence result did not agree. Third-party testing means nothing until the certificate names the metals (at least As, Pb, Hg, Cd), the limits, the method, the laboratory, and the lot. That is the fifth red-team challenge on heavy-metal safety, applied to labels.

25 Authenticity and adulteration

Ding treated origin as still “unclear and controversial” even after a field campaign (Ding et al., 2020). Aiello showed that a shared folk name can attach to glycerol ethers from petrel nests (Aiello et al., 2011). Aldakheel showed that two national labels already differ in mercury (Aldakheel et al., 2022). Hussain and Saeed reviewed the metal-versus-humic tension (Hussain and Saeed, 2024).

Adulteration, in this file, need not mean a second herb stuffed in a capsule. It can mean a different cliff, a different year, a different animal contribution, a different wash, or a rasa shastra metal that the label does not discuss. Authenticity is a chemical and geological problem. It is not a photograph of snow.

26 Human and animal safety signals

Velmurugan, Vivek, Wilson, Bharathi, and Sundaram gave black shilajit to rats at 500, 2,500, and 5,000 mg/kg for 91 days and reported histopathology and iron by atomic absorption (Velmurugan et al., 2012). That is a rodent repeat-dose study. High mg/kg numbers do not convert to a human allowance.

Biswas reported unaltered hepatic and renal profiles at 100 mg twice daily for 90 days in 28 completers (Biswas et al., 2010). Das reported the extract was well tolerated, without CK or myoglobin change, in the muscle-transcript protocol (Das et al., 2016). Das 2019 reported no adverse effect in 14 weeks in women (Das et al., 2019). Those are short human safety panels on named preparations. They are not lifetime toxicology.

Losa and colleagues reported exercise-induced anaphylaxis in which an Ayurvedic drug containing shilajit was judged a cofactor in a patient with mast-cell activation syndrome (Losa et al., 2019). The authors noted that shilajit is often described as having a high degree of safety and that it can still act as a cofactor in a high-risk setting (Losa et al., 2019). A case is not incidence. It is a stop sign for “risk-free rasayana” language.

Stohs’s reassurance that safety is “well documented” (Stohs, 2014) cannot be read after Aldakheel and Saper without the qualifier: documented on some processed preparations, in some short trials, is not documented for raw commercial resin.

Goel, Banerjee, and Acharya reported antiulcerogenic and anti-inflammatory effects of Afghan (Zarlek, Badakhshan) shilajit in experimental models (Goel et al., 1990). Ghasemkhani and colleagues reported effects on aspirin-induced gastric lesions in rats (Ghasemkhani et al., 2021). Those are animal GI papers. They are not a human ulcer indication.

27 What remains unresolved

The unresolved-science register is filed with this project. The short list: pharmacopoeial identity; independent replication of Pandit with published n and effect sizes; a placebo-controlled fertility trial with live-birth or sustained semen endpoints; a whole-sample, pre-specified fatigue trial; any adequate human cognition RCT; fracture outcomes after Pingali; metabolic RCTs; microbial surveys of retail lots; a public lot-level metal library; independence from extract sponsors.

Project 06, searched read-only, did not contain a shilajit title corpus that could substitute for NCBI. Live-catalog component hits pointed at scattered PMC records already reachable from PubMed. Project 07 journalism claims (rasayana-as-efficacy, natural TRT, fulvic-as-potency, mitochondrial energy, raw-is-safer, third-party-tested-means-safe) are discovery-only and were not ingested.

28 How to read a label after this document

Read the preparation name. If the human sentence you want to borrow came from PrimaVie, a “standardised aqueous extract,” or “processed shilajit,” the label in your hand is a different object until it is the same object.

Read the metals. If As, Pb, Hg, and Cd are not reported for that lot, Aldakheel and Saper are the prior.

Read the fulvic percentage as an assay, not a promise.

Read testosterone language against Pandit’s healthy middle-aged men and against Biswas’s missing placebo arm.

Read energy language against Keller’s subgroup and Surapaneni’s rats.

Read cognition language as a review hypothesis.

This document recommends no product, amount, route, or schedule. It is a research review.

29 Human-trial matrix

30 Chemistry matrix

31 Product-quality matrix

32 Contaminant matrix

33 Safety matrix

References